semaglutide patent date Novo Nordisk expiry opens door to cheaper weight-loss drugs in India Ozempic's Patent Protection Starts to

Key secondary endpoints included response rates (the mean percentages of patients reaching at least 50%, 75%, and 100% reduction from baseline in the number of monthly migraine headache days over the 6-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 6-month treatment period, and the impact of migraine on daily activities, as assessed by the mean change from baseline in the average Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive domain score during the last 3 months of treatment (Months 4 to 6)

Nature 429 , 4146 (2004)

Research Disclaimer For Research Use Only

Apply an appropriate amount to the lips with a gentle massage